News Sentiment

IBRX sentiment intelligence

Immunitybio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 8.22 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-12.9% over one week, +15.8% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Are Surging IBRX Retail Debates Hinting at a Deeper Re‑rating of ImmunityBio’s Platform?

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction -12.9% Price reacting lower
Trend fit Trend active 15.8% over four weeks
Fair value 93.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 33
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 10
Market source 7
Investing.com 5
Stock Titan 5
simplywall.st 4
Simply Wall Street 3
Stocktwits 3
MT Newswires 3

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 13
Analyst action 2
Deals and strategy 2
Balance sheet 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Simply Wall Street Direct company coverage

Are Surging IBRX Retail Debates Hinting at a Deeper Re‑rating of ImmunityBio’s Platform?

ImmunityBio (IBRX) is awaiting an FDA decision on its drug Anktiva for bladder cancer, with a PDUFA date of January 6, 2027. This regulatory milestone, combined with increasing retail investor interest, is influencing sentiment around the broader immunotherapy platform. The compa

Tone
Positive 62/100
Event
Analyst action
Published
15 Jul 2026 08:12
Source
Simply Wall Street
Stocktwits Direct company coverage

IBRX Stock Climbs Premarket Despite Investor Stake Cut — Retail Sees ‘Imminent’ Global Rollout Catalyst

ImmunityBio (IBRX) stock rose in premarket trading even after an institutional investor, Sheets Smith Wealth Management, cut its stake. This climb was driven by retail traders anticipating an imminent global rollout announcement for Anktiva, despite the FDA's ongoing review for b

Tone
Positive 62/100
Event
Deals and strategy
Published
14 Jul 2026 08:12
Source
Stocktwits
Simply Wall Street Direct company coverage

ImmunityBio (IBRX) Could Be 37% Below Fair Value Following Revenue Surprise Talk

ImmunityBio (IBRX) is gaining attention due to new investment firm positions and speculation about a Q2 revenue surprise and Anktiva label expansion updates. Despite a recent pullback, the stock is up significantly year-to-date and trades below its estimated fair value of $13. Th

Tone
Positive 73/100
Event
Earnings
Published
11 Jul 2026 18:12
Source
Simply Wall Street
TradingView Direct company coverage

Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise

ImmunityBio, Inc. (IBRX) saw its stock rally as institutional investors increased their holdings and retail traders anticipated a strong Q2 revenue surprise, particularly regarding Anktiva sales. Strategic Investment Solutions and Mayflower Financial Advisory significantly raised

Tone
Positive 64/100
Event
Earnings
Published
10 Jul 2026 18:12
Source
TradingView
24/7 Wall St. Direct company coverage

ImmunityBio : IBRX

ImmunityBio Inc. (IBRX) is a biotechnology company focused on developing innovative therapies and vaccines for cancers and infectious diseases, including COVID-19 and HIV. The company has a diverse pipeline encompassing immunotherapy, cell therapy, and advanced vaccine technologi

Tone
Negative 38/100
Event
Market update
Published
10 Jul 2026 16:08
Source
24/7 Wall St.
StocksToTrade Direct company coverage

IBRX Stock Steadies As Director Cheryl Cohen Unloads Shares

ImmunityBio Inc. (IBRX) stock steadied following the sale of 131,210 shares by director Cheryl Cohen for approximately $1.25 million, though she retains a significant stake. The sale comes as IBRX has experienced a strong multi-week run but faces mounting pressure from clinical t

Tone
Negative 30/100
Event
Deals and strategy
Published
10 Jul 2026 12:33
Source
StocksToTrade
Investing.com Direct company coverage

ImmunityBio director Selecky sells $1.44m in shares

ImmunityBio director Christobel Selecky sold 159,478 shares of common stock for $1.44 million on July 1, 2026, after exercising stock options. This sale, conducted via a Rule 10b5-1 trading plan, leaves Ms. Selecky with no direct shares. The company's stock (IBRX) has seen a 305%

Tone
Negative 39/100
Event
Market update
Published
07 Jul 2026 17:10
Source
Investing.com
Investing.com Direct company coverage

ImmunityBio director Cheryl Cohen sells $1.25m in stock

ImmunityBio director Cheryl Cohen sold 131,210 shares of the company's common stock for $1.25 million on July 2, 2026, while also acquiring 55,979 shares through stock options. These transactions occurred as ImmunityBio's stock has surged 227% over the past year, though it is con

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 16:39
Source
Investing.com
Stock Titan Direct company coverage

ImmunityBio (IBRX) director trades 131K shares, exercises 55,979 options

ImmunityBio, Inc. Director Cheryl Cohen reported an exercise-and-sale transaction involving the company's common stock. On July 2, 2026, she sold 131,210 shares at a weighted average price of $9.5034 per share under a pre-arranged Rule 10b5-1 trading plan. Simultaneously, Cohen e

Tone
Negative 36/100
Event
Market update
Published
07 Jul 2026 04:11
Source
Stock Titan
TradingView Direct company coverage

IBRX Stock Slips Overnight: Insider Sale Tests Retail Optimism Ahead Of FDA Growth Catalyst

ImmunityBio (IBRX) shares slipped after an independent director filed to sell over 131,000 shares, valued at $1.2 million, which cooled retail sentiment despite the stock's recent gains. Investors are now focused on the potential FDA label expansion for Anktiva for papillary blad

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 16:13
Source
TradingView
Simply Wall Street Direct company coverage

ImmunityBio (IBRX) Is Up 8.4% After Russell Index Removal Amid Anktiva Expansion Efforts - What's Changed

ImmunityBio (IBRX) saw an 8.4% stock increase despite being removed from several Russell value benchmarks. The company's investment narrative is largely tied to the expansion of its cancer drug Anktiva beyond its initial bladder cancer niche, with investors closely watching the F

Tone
Positive 61/100
Event
Market update
Published
05 Jul 2026 04:09
Source
Simply Wall Street
Finviz Direct company coverage

IBRX - ImmunityBio Inc Revenue Breakdown

This page provides a detailed financial breakdown for ImmunityBio Inc. (IBRX), including its market capitalization, enterprise value, income, sales, key financial ratios, stock performance metrics, and ownership percentages. The data presented covers various aspects of the compan

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 14:40
Source
Finviz
Investing.com Direct company coverage

ImmunityBio director Selecky sells $871k in stock

ImmunityBio director Christobel Selecky sold approximately $871,215 worth of common stock on June 29 and 30, 2026, through a pre-arranged trading plan. These sales followed the exercise of stock options to acquire shares at a lower price. Following these transactions, Selecky no

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 02:14
Source
Investing.com
Stock Titan Direct company coverage

ImmunityBio (IBRX) director pre-plans option exercises and sells 96,722 shares

ImmunityBio, Inc. director Christobel Selecky exercised stock options for 96,722 shares of Common Stock and subsequently sold all of them in pre-planned, open-market transactions on June 29-30, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on March 13, 20

Tone
Negative 40/100
Event
Market update
Published
01 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

IBRX (NASDAQ) insider exercise 1,000 shares; 95,722-share 10b5-1 sale

A Form 144 filing by ImmunityBio, Inc. (IBRX) disclosed an insider's recent stock activities. The filing detailed an exercise of 1,000 shares settled for cash on June 30, 2026, and a prior 10b5-1 sale by Christobel Selecky of 95,722 shares on June 29, 2026, for gross proceeds of

Tone
Neutral 50/100
Event
Balance sheet
Published
30 Jun 2026 20:39
Source
Stock Titan
TradingView Direct company coverage

IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales

ImmunityBio, Inc. (IBRX) stock reached a three-month high as retail traders anticipate several July catalysts, including updates on Anktiva's expansion in Saudi Arabia, potential Q2 sales performance, and the company's global manufacturing efforts. The FDA's acceptance of an expa

Tone
Positive 71/100
Event
Market update
Published
30 Jun 2026 13:40
Source
TradingView
Stock Titan Direct company coverage

[144] ImmunityBio, Inc. SEC Filing

ImmunityBio, Inc. (IBRX) filed a Form 144 with the SEC on June 29, 2026, indicating a proposed sale of 95,722 shares of common stock with an aggregate market value of $833,738.62. The shares were acquired through the exercise of stock options on the same date. The filing specifie

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 21:13
Source
Stock Titan
TradingView Direct company coverage

SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology

Sellas Life Sciences (SLS) and ImmunityBio, Inc. (IBRX) are drawing attention as the biotech sector approaches a strong monthly close, with analysts highlighting significant opportunities in immuno-oncology and other cancer treatments. Both companies are seeing their stocks perfo

Tone
Positive 73/100
Event
Analyst action
Published
29 Jun 2026 04:13
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of ImmunityBio, Inc. – NASDAQ:IBRX

This article provides a brief financial overview of ImmunityBio, Inc. (NASDAQ: IBRX), focusing on its enterprise value to EBITDA forward metric. It appears to be a stub or a section from a larger financial data platform, indicating key financial data for the company. The content

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 14:10
Source
TradingView
Investing.com Direct company coverage

ImmunityBio director Simon Barry J. sells $196,907 of common stock

ImmunityBio director Simon Barry J. has sold 25,000 shares of the company's common stock for $196,907, with shares sold at an average price of $7.8763. This sale, executed under a Rule 10b5-1 trading plan, follows a significant price appreciation for the stock, though InvestingPr

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 12:39
Source
Investing.com
TechStock² Direct company coverage

ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

ImmunityBio (NASDAQ:IBRX) saw its stock jump 11.8% on Friday, trading with significantly higher volume (41.2 million shares), which was 46% of its past five sessions' trading volume, potentially driven by the Russell reconstitution. Despite a director's planned sale of 25,000 sha

Tone
Positive 64/100
Event
Market update
Published
27 Jun 2026 10:08
Source
TechStock²
TradingView Direct company coverage

Enterprise value to EBIT forward of ImmunityBio, Inc. – NASDAQ:IBRX

This article focuses on the "Enterprise value to EBIT forward" metric for ImmunityBio, Inc. (NASDAQ: IBRX). It appears to be an entry from a financial data platform, providing a snapshot of this specific financial ratio for the company. The content itself seems to be a page from

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 08:39
Source
TradingView